Downregulation of CCR5 expression on cells by recombinant adenovirus containing antisense CCR5, a possible measure to prevent HIV-1 from entering target cells

Journal of Acquired Immune Deficiency Syndromes

Volumn 43, Issue 5, 2006, Pages 516-522

  Li, Wengang ^a   Yu, Min ^a   Bai, Li ^a   Bu, Dingfang ^a   Xu, Xiaoyuan ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

C C motif chemokine receptor 5 (CCR5); Down regulation; HIV 1; Recombinant adenovirus

Indexed keywords

CHEMOKINE RECEPTOR CCR5; COMPLEMENTARY DNA; COMPLEMENTARY RNA; MESSENGER RNA;

ADENOVIRUS; ARTICLE; CELL PROLIFERATION; CELL STRAIN U937; CHEMOTAXIS; CONTROLLED STUDY; DOWN REGULATION; ESCHERICHIA COLI; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; VIRUS CELL INTERACTION; VIRUS INHIBITION; VIRUS RECOMBINANT; WESTERN BLOTTING;

ADENOVIRIDAE; CELL PROLIFERATION; CHEMOTAXIS; DNA, ANTISENSE; DOWN-REGULATION; GENE EXPRESSION REGULATION; HIV-1; HUMANS; MONOCYTES; RANTES; RECEPTORS, CCR5; RNA, MESSENGER; U937 CELLS;

EID: 33845356330     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000243102.95640.92     Document Type: Article

References (27)

1. Derdeyn CA, Silvestri G. Viral and host factors in the pathogenesis of HIV infection. Curr Opin Immunol. 2005;17:366-373.
2. Delobel P, Sandres-Saune K, Cazabat M, et al. R5 to X4 switch of the predominant HIV-1 population in cellular reservoirs during effective highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2005;38:382-392.
3. Stauber RH, Rulong S, Palm G, et al. Direct visualization of HIV-1 entry: mechanisms and role of cell surface receptors. Biochem Biophys Res Commun. 1999;258:695-702.
4. Strayer DS, Akkina R, Bunnell BA, et al. Current status of gene therapy strategies to treat HIV/AIDS. Mol Ther. 2005;11:823-842.
5. Moore JP, Tokola A, Dragic T. Co-receptors for HIV-1 entry. Curr Opin Immunol. 1997;9:551-562.
6. Deng HK, Unutmaz D, KewalRamani VN, et al. Expression cloning of new receptors used by simian and human immunodeficiency viruses. Nature. 1997;388:296-300.
7. Dean M, Carrington M, Winkler C, et al. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Science. 1996;273:1856-1862.
8. Feng Y, Leavitt M, Tritz R, et al. Inhibition of CCR5-dependent HIV-1 infection by hairpin ribozyme gene therapy against CC-chemokine receptor 5. Virology. 2000;276:271-278.
9. Mueller A, Strange PG. Mechanisms of internalization and recycling of the chemokine receptor, CCR5. Eur J Biochem. 2004;271:243-252.
10. Bai J, Gorantla S, Banda N, et al. Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo. Mol Ther. 2000;1:244-254.
11. Lee MT, Coburn GA, McClure MO, et al. Inhibition of human immunodeficiency virus type 1 replication in primary macrophages by using Tat- or CCR5-specific small interfering RNAs expressed from a lentivirus vector. J Virol. 2003;77:11964-11972.
12. Coffield VM, Jiang Q, Su L. A genetic approach to inactivating chemokine receptors using a modified viral protein. Nat Biotechnol. 2003;21:1321-1327.
13. Samson M, Libert F, Doranz BJ, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature. 1996;382:722-725.
14. Douglas GC, Thirkill TL, Sideris V, et al. Chemokine receptor expression by human syncytiotrophoblast. J Reprod Immunol. 2001;49:97-114.
15. Qureshi A, Zheng R, Parlett T, et al. Gene silencing of HIV chemokine receptors using ribozymes and single-stranded antisense RNA. Biochem J. 2006;394(pt 2):511-518.
16. Akkina R, Banerjea A, Bai J, et al. siRNAs, ribozymes, and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS. Anticancer Res. 2003;23:1997-2005.
17. Brisibe EA, Okada N, Mizukami H, et al. RNA interference: potentials for the prevention of HIV infections and the challenges ahead. Trends Biotechnol. 2003;21:306-311.
18. Gonzalez MA, Serrano F, Llorente M, et al. A hammerhead ribozyme targeted to the human chemokine receptor CCR5. Biochem Biophys Res Commun. 1998;251:592-596.
19. Anderson J, Akkina R. HIV-1 resistance conferred by siRNA co-suppression of CXCR4 and CCR5 co-receptors by a bispecific lentiviral vector. AIDS Res Ther. 2005;2:1-12.
20. Barnor JS, Miyano-Kurosaki N, Yamaguchi K, et al. Intracellular expression of antisense RNA transcripts complementary to the human immunodeficiency virus type-1 vif gene inhibits viral replication in infected T-lymphoblastoid cells. Biochem Biophys Res Commun. 2004;320:544-550.
21. Humeau LM, Binder GK, Lu X, et al. Efficient lentiviral vector-mediated control of HIV-1 replication in CD4 lymphocytes from diverse HIV+ infected patients grouped according to CD4 count and viral load. Mol Ther. 2004;9:902-913.
22. Castagna A, Biswas P, Beretta A, et al. The appealing story of HIV entry inhibitors: from discovery of biological mechanisms to drug development. Drugs. 2005;65:879-904.
23. Peng H, Callison DE, Li P, et al. Enhancement or inhibition of HIV-1 replication by intracellular expression of sense or antisense RNA targeted at different intermediates of reverse transcription. AIDS. 1997;11:587-595.
24. Michienzi A, Castanotto D, Lee N, et al. RNA-mediated inhibition of HIV in a gene therapy setting. Ann NY Acad Sci. 2003;1002:63-71.
25. Coakley E, Petropoulos CJ, Whitcomb JM. Assessing chemokine co-receptor usage in HIV. Curr Opin Infect Dis. 2005;18:9-15.
26. Duggal P, Winkler CA, An P, et al. The effect of RANTES chemokine genetic variants on early HIV-1 plasma RNA among African-American injection drug users. J Acquir Immune Defic Syndr. 2005;38:584-589.
27. Santoro F, Vassena L, Lusso P. Chemokine receptors as new molecular targets for antiviral therapy. New Microbiol. 2004;27(Suppl 1):17-29.